Loading company…
Prophylix Pharma develops treatments for rare medical conditions, including NAITgam for fetal and neonatal alloimmune thrombocytopenia.
Prophylix Pharma develops therapies for rare conditions, with a focus on NAITgam, a plasma-derived antibody in early clinical development for fetal and neonatal alloimmune thrombocytopenia. The company is based in Tromso, Norway, and was founded in 2008. It raised NOK 2.000 mn from Norrinova Invest.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in